Treatment 1 Treatment 2 I2 (Weeks 12–16) I2 Sensitivity Analysis (Weeks 12–16) I2 (Weeks 24–28)
PASI 75
Placebo Tildrakizumab 100 mg 0.0% 0.0% 0.0%
Placebo Guselkumab 100 mg 9.3% 0.0% 0.0%
PASI 90
Placebo Tildrakizumab 100 mg 0.0% 0.0% 0.0%
Placebo Guselkumab 100 mg 0.0% 0.0% 0.0%
SAE
Placebo Tildrakizumab 100 mg 34.1% 34.1% 3.9%
Placebo Guselkumab 100 mg 0.0% 0.0% NA
Discontinuations
Placebo Tildrakizumab 100 mg 0.0% 0.0% 84.5%
Placebo Guselkumab 100 mg 0.0% 39.3% NA